Dark

IPHA
Innate Pharma S.A. ADS
stock NASDAQ ADR

At Close

May 16, 2025

2.11USD0.000%(0.00)9,045

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 16, 2025 8:00:30 AM EDT

2.11USD+0.005%(+0.00)1,000

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 24, 2022

01:00AM EST Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022 Business Wire

Jan 18, 2022

05:40AM EST INNATE PHARMA Granted U.S. Patent #11,225,519 'Treatment of cancers using anti-NKG2A agents' Benzinga

Jan 5, 2022

08:20AM EST The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets Benzinga

01:04AM EST Innate Pharma Obtains EUR 28.7 Mln In Non-dilutive financing In Form Of Two Loans From Socit Gnrale And BNP Paribas RTTNews

01:00AM EST Innate Pharma Obtains (euro)28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans Business Wire

Jan 4, 2022

01:00AM EST Innate Pharma to Participate in Upcoming Investor Conferences Business Wire

Dec 28, 2021

11:21AM EST Innate Pharma Granted U.S. Patent Titled 'Multispecific antigen binding proteins' Benzinga

Dec 16, 2021

01:18AM EST Innate Pharma SA (IPHA) said that the first patient was dosed in a Phase 1/2 clinical trial (NCT05086315), evaluating IPH6101/SAR443579, the first NKp46/CD16-based NK cell engager, in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplastic syndrome (HR-MDS). RTTNews

01:05AM EST Innate Pharma Says First Patient Dosed In IPH6101/SAR443579 Phase 1/2 Clinical Trial In Various Blood Cancers RTTNews

01:00AM EST Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers Business Wire

Dec 9, 2021

09:46PM EST The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO Benzinga

05:00AM EST Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress Business Wire

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 2, 2021

06:07AM EST Innate Pharma To Present Monalizumab Data At ESMO Immuno-Oncology 2021 Congress RTTNews

Nov 24, 2021

01:00AM EST Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference Business Wire

Nov 16, 2021

01:05AM EST Innate Pharma 9-month Revenues Decline To EUR 10.3 Mln From EUR 33.6 Mln Prior Year RTTNews

01:00AM EST Innate Pharma Third Quarter 2021 Report Business Wire

Nov 12, 2021

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

Nov 9, 2021

01:00AM EST Innate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update Business Wire

Oct 26, 2021

01:00AM EDT Innate Pharma 2022 Financial Calendar Business Wire

Oct 15, 2021

01:00AM EDT Number of Shares and Voting Rights of Innate Pharma as of October 1, 2021 Business Wire

Oct 8, 2021

03:42PM EDT Innate Pharma Granted Australian Patent Titled 'Treatment of cancers using anti-NKG2A agents' Benzinga

Sep 30, 2021

06:30AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.15 A.M. EDT). RTTNews

Sep 23, 2021

01:00AM EDT Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: GlobeNewswire Inc

Sep 17, 2021

03:10PM EDT Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet Benzinga

12:12PM EDT Mid-Day Market Update: Crude Oil Falls Over 1%; Helbiz Shares Spike Higher Benzinga

11:28AM EDT Shares of Innate Pharma S.A. (IPHA) are surging over 60% on Friday morning after its partner AstraZeneca Plc (AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology Congress 2021. RTTNews

10:19AM EDT Mid-Morning Market Update: Markets Down; US Consumer Sentiment Edges Higher Benzinga

07:47AM EDT Innate Pharma Highlights Monalizumab Data From COAST Trial Presented At European Society Of Medical Oncology Congress Benzinga

07:45AM EDT Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021. GlobeNewswire Inc

07:39AM EDT 10 Biggest Price Target Changes For Friday Benzinga

05:31AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 5.10 A.M. EDT). RTTNews

04:42AM EDT SVB Leerink Maintains Outperform on Innate Pharma, Raises Price Target to $9 Benzinga

Sep 15, 2021

04:25AM EDT Earnings Scheduled For September 15, 2021 Benzinga

01:11AM EDT Innate Pharma H1 Net Loss EUR 23.7 Mln Vs Loss Of EUR 10.3 Mln Last Year RTTNews

01:00AM EDT Innate Pharma Reports First Half 2021 Financial Results and GlobeNewswire Inc

Sep 7, 2021

06:25AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 6.10 A.M. EDT). RTTNews

01:00AM EDT Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Wednesday, September 15, 2021, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2021. GlobeNewswire Inc

Sep 3, 2021

10:01AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 3, 2021 Benzinga

09:01AM EDT Benzinga Pro's Top 5 Stocks To Watch For Friday, Sept. 3, 2021: LULU, ROKU, ANY, APOP, IPHA Benzinga

06:41AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 6.30 A.M. EDT). RTTNews

05:26AM EDT SVB Leerink Upgrades Innate Pharma to Outperform Benzinga

Sep 2, 2021

04:14PM EDT Innate Pharma Shares Spike ~5% Afterhours; SVB Leerink Upgraded The Stock To Outperform And Maintained A $7 Price Target Benzinga

04:12PM EDT Innate Pharma Shares Spike ~5% Afterhours; Hearing SVB Leerink Upgraded The Stock To Outperform And Announced A $7 Price Target Benzinga

12:05PM EDT Mid-Day Market Update: Crude Oil Jumps Over 2%; Assembly Biosciences Shares Plunge Benzinga

10:49AM EDT Innate Pharma S.A. (IPHA) shares are rising more than 29 percent on Thursday morning trade. The company said AstraZeneca will make two oral presentations on COAST phase 2 trial of Innate's monalizumab in combination with durvalumab. Further, Innate will present pre-clinical data from multi specific NK cell engager platform ANKET. RTTNews

10:18AM EDT Mid-Morning Market Update: Markets Open Higher; Hormel Foods Cuts Earnings Outlook Benzinga

07:03AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.45 A.M. EDT). RTTNews

02:00AM EDT Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that two oral presentations will be highlighted at the ESMO 2021 Virtual Congress. GlobeNewswire Inc

Aug 30, 2021

01:00AM EDT Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) today announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences: GlobeNewswire Inc

Aug 11, 2021

01:00AM EDT Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (the Company - Euronext Paris: FR0010331421 IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of August 1, 2021: GlobeNewswire Inc

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 12, 2021

01:00AM EDT Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (the Company - Euronext Paris: FR0010331421 IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of July 1, 2021: GlobeNewswire Inc

Jul 6, 2021

07:16AM EDT Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints Benzinga

01:25AM EDT Innate Pharma SA (IPHA) announced Tuesday that the investigator-sponsored Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with severe pneumonia did not meet primary endpoints in all three cohorts of the trial. RTTNews

01:00AM EDT Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients GlobeNewswire Inc

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 22, 2021

09:32AM EDT Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients Benzinga

08:12AM EDT The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal Benzinga

07:20AM EDT Intema Signs LoI To Acquire Team BloodHounds Inc., Owner Of The Team BH Esports Team RTTNews

07:16AM EDT Innate Pharma Presents Preliminary Data From Mycosis Fungoides Cohort Of Phase 2 TELLOMAK Trial RTTNews

07:01AM EDT Innate Pharma Highlights Presentation Of Preliminary Data from TELLOMAK Trial Benzinga

07:00AM EDT First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 GlobeNewswire Inc

Jun 16, 2021

01:00AM EDT Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) today announced that it will host a virtual investor event on Wednesday, June 23, 2021, at 2 p.m. CEST / 8 a.m. EDT. GlobeNewswire Inc

Jun 14, 2021

01:00AM EDT Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (the Company - Euronext Paris: FR0010331421 IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of June 1, 2021: GlobeNewswire Inc

Jun 10, 2021

01:06AM EDT Innate Pharma Presents New Data On Next-Generation NK Cell Engager Platform, ANKET, At FOCIS 2021 Annual Meeting RTTNews

01:00AM EDT Innate Pharma Presents New Data on Next-Generation NK Cell Engager GlobeNewswire Inc

Jun 9, 2021

06:14AM EDT Innate Pharma To Present Data From Tellomak Trial At 16th International Conference on Malignant Lymphoma Jun. 22 Benzinga

06:00AM EDT New Lacutamab Data From Tellomak Trial to be Showcased in Oral GlobeNewswire Inc

May 28, 2021

04:01PM EDT Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) announced the voting results of its shareholders at the Annual General Meeting (AGM), which took place on May 28, 2021, in Marseille, France without the physical presence of its shareholders. All resolutions were voted on in accordance with the Executive Boards recommendations. GlobeNewswire Inc

May 25, 2021

01:00AM EDT Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (the Company - Euronext Paris: FR0010331421 IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of May 1, 2021: GlobeNewswire Inc

May 12, 2021

01:00AM EDT Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) has published the convening notice to the Bulletin des Annonces Lgales Obligatoires for its Annual General Meeting of Shareholders (AGM), which will take place virtually at 11:00 a.m. CEST on May 28, 2021. GlobeNewswire Inc

May 11, 2021

12:47PM EDT Earnings Scheduled For May 11, 2021 Benzinga

01:41AM EDT Innate Pharma Q1 Revenues EUR 4.5 Mln Vs EUR 19.3 Mln Last Year RTTNews

01:00AM EDT -- Lacutamab TELLOMAK trial progresses as KIR3DL2-expressing mycosis fungoides cohort advances to Stage 2 after positive early signal -- Companys first NK cell engager selected by Sanofi as drug candidate for development -- Cash position of 181.7 millionas of March 31, 2021 GlobeNewswire Inc

May 4, 2021

01:00AM EDT Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, May11, 2021 at 3 p.m. CEST / 9 a.m. ET, to give an update on business progress during the first quarter of 2021. GlobeNewswire Inc

Apr 28, 2021

01:00AM EDT Innate Pharma Files Its 2020 Universal Registration Document GlobeNewswire Inc

Apr 21, 2021

01:00AM EDT Innate Pharma to Hold Its Annual General Meeting of Shareholders GlobeNewswire Inc

Apr 19, 2021

01:00AM EDT Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (the Company Euronext Paris: FR0010331421 IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at April 1, 2021: GlobeNewswire Inc

Mar 19, 2021

06:21AM EDT SVB Leerink Maintains Market Perform on Innate Pharma, Raises Price Target to $7 Benzinga

Mar 18, 2021

02:00AM EDT Innate Pharma Reports Full Year 2020 Financial(1) Results and GlobeNewswire Inc

Mar 16, 2021

02:00AM EDT Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, March18, 2021 at 2 p.m. CET / 9 a.m. ET, following the release of its financial results for the full year ending December 31, 2020. GlobeNewswire Inc

Feb 24, 2021

01:00AM EST Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (the Company - Euronext Paris: FR0010331421 IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of February 1, 2021: GlobeNewswire Inc

Feb 17, 2021

01:00AM EST Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference: GlobeNewswire Inc

Feb 9, 2021

07:19AM EST Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients Benzinga

01:00AM EST TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated GlobeNewswire Inc

Feb 3, 2021

01:00AM EST Innate Pharma to Host Key Opinion Leader Discussion on the GlobeNewswire Inc

Jan 5, 2021

05:50AM EST Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development Benzinga

01:00AM EST -- IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innates proprietary multispecific antibody format -- Selection of IPH6101/SAR443579 triggers a 7M milestone payment to Innate GlobeNewswire Inc

Jan 4, 2021

Dec 22, 2020

09:12AM EST INNATE FINAL DEADLINE: ROSEN, A LONSTANDING LAW FIRM, Reminds GlobeNewswire Inc

Dec 21, 2020

07:31PM EST The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Innate Pharma, S.A. (NASDAQ: IPHA) investors that acquired shares between March 10, 2020 and September 8, 2020. Investors have until December 22, 2020 to seek an active role in this litigation. GlobeNewswire Inc

07:14PM EST Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire

11:30AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

11:00AM EST IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff Deadline: December 22, 2020 Business Wire

Dec 18, 2020

11:47AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 17, 2020

07:45PM EST ROSEN, A LEADING LAW FIRM, Reminds Innate Pharma S.A. Investors of GlobeNewswire Inc

Dec 16, 2020

12:00PM EST LVS, IPHA & JPM Looming Deadlines: Bronstein, Gewirtz & Grossman GlobeNewswire Inc

11:00AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Dec 15, 2020

06:53PM EST Investors of Important December 22 Deadline in Securities Class Action - IPHA PR Newswire

11:00AM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

06:10AM EST SVB Leerink Downgrades Innate Pharma to Market Perform, Lowers Price Target to $5 Benzinga

Dec 14, 2020

01:00PM EST Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming PR Newswire

06:19AM EST HC Wainwright & Co. Maintains Buy on Innate Pharma, Lowers Price Target to $11.5 Benzinga

Dec 12, 2020

10:31PM EST Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (Innate or the Company) (NASDAQ:IPHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Dec 11, 2020

12:20PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the Class Period). GlobeNewswire Inc

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

01:00AM EST Innate Pharma to Return US and EU Lumoxiti Commercialization GlobeNewswire Inc

Dec 9, 2020

04:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

12:00PM EST Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingDecember 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA (Innate or the "Company") (NASDAQ: IPHA) securities between March 10, 2020 and September 8, 2020, inclusive (the Class Period). GlobeNewswire Inc

11:15AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

10:00AM EST LVS, IPHA & JPM Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

09:06AM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws. GlobeNewswire Inc

Dec 7, 2020

08:56PM EST Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (Innate or the Company) (NASDAQ:IPHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

12:30PM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 4, 2020

06:30PM EST ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Innate Pharma S.A. GlobeNewswire Inc

Dec 3, 2020

10:07AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the Class Period). GlobeNewswire Inc

08:30AM EST Innate Pharma to Present Additional Efficacy Data for Monalizumab GlobeNewswire Inc

04:45AM EST SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

Dec 2, 2020

06:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

01:00AM EST Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) today released its 2021 financial calendar: GlobeNewswire Inc

12:30AM EST December 22 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact the Firm - IPHA PR Newswire

Dec 1, 2020

11:00AM EST LVS, IPHA & JPM Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

Nov 30, 2020

10:28PM EST Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (Innate or the Company) (NASDAQ:IPHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 26, 2020

03:00PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws. GlobeNewswire Inc

Nov 25, 2020

11:02PM EST Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (Innate or the Company) (NASDAQ:IPHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 24, 2020

05:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

11:01AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the Class Period). GlobeNewswire Inc

05:58AM EST Goldman Sachs Initiates Coverage On Innate Pharma with Neutral Rating, Announces Price Target of $4.75 Benzinga

Nov 23, 2020

Nov 21, 2020

01:07PM EST LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors with Losses PR Newswire

Nov 20, 2020

06:56PM EST ROSEN, LEADING INVESTOR COUNSEL, Reminds Innate Pharma S.A. GlobeNewswire Inc

Nov 19, 2020

11:38AM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws. GlobeNewswire Inc

Nov 18, 2020

07:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

11:45AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Nov 17, 2020

09:29AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the Class Period). GlobeNewswire Inc

01:07AM EST Innate Pharma 9-month Revenues EUR 33.6 Mln Vs EUR 65.4 Mln Last Year RTTNews

01:00AM EST -- Lacutamab granted PRIME designation inSzary Syndrome by the European Medicines Agency -- Monalizumab Phase 3 study initiated, triggering $50 million milestone payment -- Cash position of 163.6 million1 as of September 30, 2020 GlobeNewswire Inc

Nov 14, 2020

02:00PM EST December 22 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses Exceeding $100K to Contact Firm - IPHA PR Newswire

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

01:00AM EST Innate Pharma Receives Prime Designation From the European GlobeNewswire Inc

Nov 12, 2020

01:00AM EST Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company), today announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences. GlobeNewswire Inc

Nov 11, 2020

05:27PM EST Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (Innate or the Company) (NASDAQ:IPHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

03:37PM EST ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds Innate Pharma GlobeNewswire Inc

11:00AM EST LVS, IPHA & JPM Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

Nov 8, 2020

12:35AM EST Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (Innate or the Company) (NASDAQ:IPHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 6, 2020

Nov 4, 2020

03:49PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws. GlobeNewswire Inc

Nov 3, 2020

04:41PM EST ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Innate Pharma S.A. GlobeNewswire Inc

Nov 2, 2020

11:00AM EST IPHA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Innate Pharma S.A. Shareholders of Class Action and Lead Plaintiff Deadline: December 22, 2020 Business Wire

Oct 30, 2020

08:13PM EDT Deadline in First Filed Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - IPHA PR Newswire

Oct 27, 2020

03:29PM EDT Shareholder Alert: Robbins LLP Announces It Is Investigating Innate Pharma S.A. PR Newswire

11:01AM EDT Pharma S.A. Shareholders of Class Action and Lead Plaintiff Deadline: December 22, 2020 PR Newswire

Oct 26, 2020

07:44PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

06:00PM EDT Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Innate investors under the federal securities laws. GlobeNewswire Inc

06:00PM EDT INNATE PHARMA ALERT: Bragar Eagel & Squire, P.C. Announces That a GlobeNewswire Inc

Oct 25, 2020

11:00AM EDT IPHA LOSS NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Announces Filing of PR Newswire

Oct 23, 2020

08:00PM EDT Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Innate Pharma S.A. (NASDAQ: IPHA) on behalf of Innate stockholders. Our investigation concerns whether Innate has violated the federal securities laws and/or engaged in other unlawful business practices. GlobeNewswire Inc

01:00AM EDT First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers GlobeNewswire Inc

Oct 13, 2020

01:00AM EDT Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) releases its total number of shares outstanding as well as its voting rights as at October 1, 2020: GlobeNewswire Inc

Sep 9, 2020

08:45AM EDT SVB Leerink Maintains Outperform on Innate Pharma, Lowers Price Target to $7 Benzinga

Sep 8, 2020

03:35AM EDT Earnings Scheduled For September 8, 2020 Benzinga

01:11AM EDT Innate Pharma H1 Net Loss EUR 10.3 Mln Vs Income Of EUR 13.2 Mln Last Year RTTNews

01:00AM EDT -- Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Szary syndrome and mycosis fungoides -- Monalizumab Phase 3 study expected to initiate in the second half of 2020, triggering $50 million milestone payment -- Innate to explore avdoralimab in inflammation beyond COVID-19 -- Cash position of 184.6 million1 as of June 30, 2020 GlobeNewswire Inc

Sep 4, 2020

01:00AM EDT Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) announces that it plans to participate in the following upcoming virtual investor conferences in September 2020: GlobeNewswire Inc

Aug 11, 2020

01:00AM EDT Innate Pharma Obtains 6.8M in Public Funding for GlobeNewswire Inc

Jul 29, 2020

05:30AM EDT Innate Pharma Announces Publication of EXPLORE COVID-19 GlobeNewswire Inc

Jul 16, 2020

01:00AM EDT Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) today announced the appointment of Dr. Joyson Karakunnel as Executive Vice President and Chief Medical Officer (CMO). Dr. Pierre Dodion, CMO since 2014, is retiring from this position. GlobeNewswire Inc

.dark-mode .FBsKbf{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .FBsKbf{ color: #333333; background-color: white; border: 2px solid #333333; }IPHAInnate Pharma S.A. ADSstock NASDAQ ADR

IPHA
Innate Pharma S.A. ADS
stock NASDAQ ADR